<SEC-DOCUMENT>0001513162-20-000056.txt : 20200318
<SEC-HEADER>0001513162-20-000056.hdr.sgml : 20200318
<ACCEPTANCE-DATETIME>20200317221018
ACCESSION NUMBER:		0001513162-20-000056
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200317
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20200318
DATE AS OF CHANGE:		20200317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	DENTAL EQUIPMENT & SUPPLIES [3843]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		20723072

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<head><title>Form 8-K</title> </head> <body lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>SECURITIES AND EXCHANGE COMMISSION</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>WASHINGTON, D.C.</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>FORM 8-K</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>CURRENT REPORT</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Pursuant to Section 13 or 15(d) of the</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Securities Exchange Act of 1934</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March 17, 2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Date of Report (date of earliest event reported)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><u>BIOMERICA, INC.</u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Exact Name of Registrant as Specified in its Charter)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=533 bordercolor=transparent style=WIDTH:400pt cellpadding=0 cellspacing=0> <tr> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; BORDER-LEFT:0px; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Delaware</p></td> <td width=43 style="WIDTH:32.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; BORDER-LEFT:0px; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN-LEFT:0in; MARGIN-RIGHT:0in' align=center>0-8765</p></td> <td width=43 style="WIDTH:32.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; BORDER-LEFT:0px; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt 1.5pt; TEXT-INDENT:-1.5pt' align=center>95-2645573</p></td></tr> <tr> <td width=93 style="WIDTH:69.75pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN-LEFT:0in; MARGIN-RIGHT:0in' align=center>(State or Other Jurisdiction of Incorporation)</p></td> <td style="PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td width=83 style="WIDTH:62.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Commission <br>File Number)</p></td> <td style="PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td width=138 style="WIDTH:103.5pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(IRS Employer Identification Number)</p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>17571 Von Karman Ave.</p> <h1 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0in 0in 0pt'>Irvine, California 92614</h1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Address of Principal Executive Offices</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Including Zip Code)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><u>949-645-2111</u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Registrant&#146;s Telephone Number,</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Including Area Code)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>___________</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Former Name or Former Address if Changed</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Since Last Report)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Page 1 of 2 pages</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>1</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b>Item 8.01&nbsp; Other Events</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b>&nbsp;&nbsp;&nbsp;&nbsp; </b>On March 17, 2020, Biomerica, Inc., issued the attached press release.</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>(d)&nbsp; Exhibits</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>Exhibit</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><u>Number</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Description</u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Press Release</u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>2</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <h2 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0in 0.3in 0pt 0in'>SIGNATURES</h2> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0.3in 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0.3in 0pt 0in'>&nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0.3in 0pt 0in' align=right>&nbsp;</p> <table width=600 bordercolor=transparent style="WIDTH:6.25in; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><a name=T13><font style="FONT-SIZE:11pt; COLOR:black">Dated:&nbsp; March 17, 2020</font></a></p></td> <td width=47% colspan=2 nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Biomerica, Inc.</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> </tr><tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">By:</font></p></td> <td width=47% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:47%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">/s/&nbsp;Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Chief Executive Officer</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>3</font></p></div></body>
<!-- EDGAR Validation Code: 62546512 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<head> <title>Exhibit 99.1</title></head> <body vlink=#954f72 link=#0071bb lang=EN-US><img src=image1.jpg> <div style=page:WordSection1> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 12pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:6pt 0in 0pt; LINE-HEIGHT:normal'><b><font style="FONT-SIZE:17.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica Begins Shipping Samples of 10 Minute Test for COVID-19 Virus Exposure </font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt 0.5in; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.25in'><font style="FONT-SIZE:13.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">-<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><b><font style="FONT-SIZE:13.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">10-minute test for coronavirus exposure utilizing blood from a finger prick can be performed anywhere by trained professionals, e.g. airports, schools, work, doctor&#146;s office </font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt 0.5in; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.25in'><font style="FONT-SIZE:13.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">-<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><b><font style="FONT-SIZE:13.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica has begun shipping samples of this COVID-19 test to multiple Ministries of Health and government agencies that have requested the product through the Company&#146;s distributors in the Middle East, Europe, and other countries </font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in; LINE-HEIGHT:107%'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.25in'><font style="FONT-SIZE:13.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">-<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><b><font style="FONT-SIZE:13.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Price point of this single-use, disposable product as low as $10 per patient </font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in; LINE-HEIGHT:107%'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.25in'><font style="FONT-SIZE:13.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">-<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><b><font style="FONT-SIZE:13.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica has filed a provisional patent on rapid test technology to identify multiple coronavirus strains including the strain responsible for COVID-19&nbsp;&nbsp; </font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt 0.5in; LINE-HEIGHT:107%'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">IRVINE, CA--(March 17, 2020) - Biomerica Inc. (NASDAQ: </font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#0071bb">BMRA</font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">) today announced it has </font>&nbsp;<font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">commenced shipping initial samples of its COVID-19 IgG/IgM Rapid Test (a finger prick blood test with results in 10 minutes, that can be performed by trained professionals anywhere, e.g. airports, schools, work, pharmacies and doctors&#146; offices) to countries outside the US. Evaluation test kits have been requested by Ministries of Health in multiple countries through the Company&#146;s distribution partners who are working with their government agencies to assess the tests and forecast demand.&nbsp; This disposable point-of-care serology test is different than the current polymerase chain reaction (PCR) tests in that initial studies indicate that serology tests can identify if someone has been exposed to the COVID-19 virus, and can further detect if a person was recently infected with the disease even if they have never shown or are no longer showing symptoms.&nbsp; This can help health agencies focus on prior contacts of persons previously infected. Existing PCR tests generally only show positive if a person is currently infected and the virus is still present.&nbsp; Furthermore, PCR tests require patient samples to be sent to a lab, thus increasing the cost of the test and reducing the speed to obtain a result. Biomerica&#146;s test could also be used in conjunction with the PCR test by rapidly pre-screening larger groups of individuals, who if tested positive could be further tested using a PCR test for verification. </font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica is positioned to begin filling large international orders of this disposable one-use tests within weeks, assuming international product shipping channels remain open and active<b>.&nbsp; &nbsp;&nbsp;</b></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">In addition, Biomerica has begun the application process with the FDA under the COVID-19 Emergency Use Authorization (EUA), aimed at the possible clearance and eventual use of the test in the US. At this time, the product is not available for sale or use in the US.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">1</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40"> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica is also announcing that it has filed a provisional patent application with broad claims around technology that can be used to identify several Corona viruses including SARS-CoV-2, SARS, MERS and potential future mutations or strains of these viruses.&nbsp; </font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica expects to sell these disposable, single-use devices for less than $10 per test.&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><b><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">About Serology Tests</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica&#146;s rapid-test technology is a serology test. Serology tests look for the presence of antibodies, which are specific proteins made in response to infections. The antibodies detected by serology tests indicate that a person has had an immune response to the novel Corona Virus (SARS CoV-2), whether symptoms developed from infection or the infection was asymptomatic. Antibody test results are important in detecting infections with few or no symptoms. <sup>1</sup></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Zackary Irani, Chairman and Chief Executive Officer, stated, &#147;We are saddened by the continued global spread of the SARS-CoV-2 virus and the devastating effects on the lives of people affected by COVID-19. While the Biomerica test is new and being evaluated by various institutions, we are hopeful our low-cost test can be one of the tools used to contain this virus while vaccines and other permanent solutions are developed. &nbsp;</font>&nbsp;<font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Our launch of this COVID-19 test is by no means a shift in the Company&#146;s stated strategy of growing both our colorectal disease detection product, finalizing clinical trials and gaining FDA approval for our HP Detect</font><font style="FONT-SIZE:10.5pt; COLOR:#002c40">&#153;</font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40"><i>H. Pylori</i> test and our InFoods&#174; IBS therapy product.&nbsp; We were simply unable to ignore our ability to help address the continued international threat of COVID-19 by utilizing our deep industry connections, experience in the diagnostics space, and ability to rapidly deploy company resources.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:9pt; FONT-FAMILY:Avenir; COLOR:#002c40">1. Emerging Microbes &amp; Infections 2020, VOL. 9 Molecular and serological investigation of 2019-nCoV infected patients.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><b><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">About Biomerica (NASDAQ: </font></b><b><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#0071bb">BMRA</font></b><b><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">)</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica, Inc. (</font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#0071bb">www.biomerica.com</font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">) is a global biomedical company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focus is on Gastrointestinal and inflammatory Diseases where the Company has multiple diagnostic and therapeutic products in development. </font></p><br> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 8pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the efficacy of the Company&#146;s COVID-19 test, the rapidity of testing results, pricing of the Company&#146;s test kits, demand for international orders, availability of the Company&#146;s COVID-19 test kits, and patent protection on the rapid test technology. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation:&nbsp; results of studies testing the efficacy of the Company&#146;s COVID-19 test; regulatory approvals necessary prior to commercialization of the Company&#146;s COVID-19 test; availability of the Company&#146;s COVID-19 test kits; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our COVID-19 test; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulations and the Company&#146;s ability to obtain patent protection on any aspects of its rapid test technology. &nbsp;Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt; LINE-HEIGHT:22.5pt'><b><font style="FONT-SIZE:11.5pt; FONT-FAMILY:Avenir; TEXT-TRANSFORM:uppercase">Contact Information</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt 0.25in; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Company Spokesperson<br>949-645-2111<br></font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#0071bb">www.biomerica.com</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 8pt; LINE-HEIGHT:normal' align=center><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">2</font></p></div></body>
<!-- EDGAR Validation Code: 2410EF2E -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (" @(" 0(" @(# @(# P8$ P,#
M P<%!00&" <)" @'" @)"@T+"0H,"@@("P\+# T.#@\."0L0$1 .$0T.#@[_
MVP!# 0(# P,# P<$! <."0@)#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.
M#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@[_P  1"  B .L# 2(  A$! Q$!_\0
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-&E1114GY"%%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
